Spyre Therapeutics (SYRE) Receivables (2018 - 2024)

Spyre Therapeutics (SYRE) has 8 years of Receivables data on file, last reported at $5.9 million in Q3 2024.

• Quarterly Receivables rose 3519.63% year-over-year to $5.9 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $5.9 million (up 3519.63% YoY) and the FY2022 annual result came in at $375000.0, down 53.99% from the prior year.
• Receivables steadied at $5.9 million in Q3 2024, from $5.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $21.5 million in Q1 2021 to a low of $163000.0 in Q3 2023.
• A 4-year average of $3.5 million and a median of $815000.0 in 2021 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables slumped 95.29% — and 2024, when it soared 3519.63%.
• Tracing SYRE's Receivables over 4 years: stood at $815000.0 in 2021, then tumbled by 53.99% to $375000.0 in 2022, then tumbled by 56.53% to $163000.0 in 2023, then soared by 3519.63% to $5.9 million in 2024.
• The last three Receivables figures came in at $5.9 million (Q3 2024), $5.9 million (Q2 2024), and $163000.0 (Q3 2023), per Business Quant data.